Heron Therapeutics Q3 EPS $(0.17) Beats $(0.29) Estimate, Sales $31.43M Miss $32.75M Estimate
Portfolio Pulse from Benzinga Newsdesk
Heron Therapeutics (NASDAQ:HRTX) reported Q3 earnings with an EPS of $(0.17), surpassing the $(0.29) estimate, marking a 55.26% improvement from last year. However, sales of $31.43M fell short of the $32.75M estimate, despite being 18.36% higher than the previous year.
November 14, 2023 | 9:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Heron Therapeutics exceeded EPS estimates but missed on revenue for Q3, showing mixed financial performance.
The positive EPS beat may provide some upward momentum, but the sales miss could temper gains. The mixed results lead to a neutral short-term impact score.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100